(Q46162379)

20 December 2017

title

Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs (English)

1 reference

20 December 2017

1 reference

Jing Tan

1

1 reference

20 December 2017

Jingguo Zhou

series ordinal

2

1 reference

20 December 2017

Pan Zhao

series ordinal

3

1 reference

20 December 2017

Jing Wei

series ordinal

4

1 reference

20 December 2017

publication date

28 April 2012

1 reference

20 December 2017

published in

Clinical Rheumatology

1 reference

20 December 2017

volume

31

1 reference

20 December 2017

issue

8

1 reference

20 December 2017

page(s)

1169-1175

1 reference

20 December 2017

Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Hepatitis B reactivation after chemotherapy: two decades of clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Evaluation of algorithms for the diagnostic assessment and the reentry of blood donors who tested reactive for antibodies against hepatitis B core antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Reactivation of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Is screening for hepatitis necessary in diagnostic evaluation of rheumatoid arthritis in South Korea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-1988-2

Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis

21 January 2018

1 reference

12 December 2020

Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients

1 reference

12 December 2020

Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs

1 reference

12 December 2020

Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate

1 reference

12 December 2020

Acute type B hepatitis among HBsAg negative patients detected by anti-HBc IgM

1 reference

12 December 2020

Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate

1 reference

12 December 2020

Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.

1 reference

12 December 2020

Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases.

1 reference

12 December 2020

Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy.

1 reference

12 December 2020

Recommendations for identification and public health management of persons with chronic hepatitis B virus infection

1 reference

12 December 2020

10.1007/S10067-012-1988-2

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017